Future Fuel 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- FutureFuel reported 3rd quarter 2026 revenue of $104.7 million, up 361.3% from $22.7 million in the 3rd quarter of 2025; the $82 million increase comprised $36.3 million from volume and product mix and $45.7 million from pricing, principally in Biofuels.
- Total gross loss was $5.4 million versus $6.5 million a year earlier, net loss was $8.4 million versus $9.2 million, and adjusted EBITDA was a loss of $4.9 million versus a loss of $5.3 million.
- Biofuels revenue was $87.8 million versus $7.1 million, while the segment reported a gross loss of $9.8 million versus $2.4 million; higher sales volumes and stronger pricing realization were more than offset by elevated input costs and increased plant operating and fixed manufacturing expenses.
- Biofuels capacity utilization increased to 83% in the 3rd quarter from 56% in the 2nd quarter, and exceeded 80% for the first time in more than 2 years.
- Chemical segment revenue was $16.9 million, up 8.6% from $15.6 million; gross profit was $4.4 million versus a loss of $4.1 million, while capacity utilization was 32% compared with 55% a year earlier.
- Custom chemical revenue was $13.3 million, down 8% from $14.5 million, primarily due to delayed shipments and production downtime; performance chemical revenue was $3.6 million, up 223% from $1.1 million, primarily due to higher volumes from a new customer and higher glycerin sales.
- The company reported $8.3 million of realized derivative losses and $0.4 million of unrealized derivative losses; $2.3 million of realized losses related to physical inventory not yet sold and was expected to be recovered in the 4th quarter.
- As of September 30th, 2026, FutureFuel had $21.3 million of cash and equivalents, down from $34.3 million at June 30th, 2026, and a $35 million revolving credit facility with no outstanding borrowings.
- Net cash used in operations was $10.3 million in the 3rd quarter, compared with $1.1 million in the prior-year period; capital expenditures were $3.3 million, including $0.6 million for maintenance and $2.7 million for discretionary programs.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Welcome to the FutureFuel Third Quarter 2026 Results Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star 0 on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Rose Sparks, Chief Financial Officer. Thank you. You may begin.
Thank you. Good morning, and welcome to the FutureFuel Third Quarter 2026 Results Conference Call. Leading the call today are our Chairman and CEO, Roeland Polet, and I am Rose Sparks, the company's Chief Financial Officer. After the close of U.S. trading yesterday, we issued a press release detailing our third quarter operational and financial results. This release is publicly available in the Investor Relations section of our corporate website at www.futurefuelcorporation.com. I would like to remind you that management's commentary and responses to questions on today's call may include forward-looking statements, which by their nature are uncertain and outside the company's control. Although these forward-looking statements are based on management's current expectations and beliefs, actual results could differ materially. For a discussion of some of the factors that could cause actual results to differ, please refer to the Risk Factors section of our latest reports filed with the SEC.
Additionally, please note that you can find reconciliations of all our historical non-GAAP financial measures mentioned on this call in the press release issued yesterday. Today's call will begin with prepared remarks from Roeland Polet, who will provide a business update, followed by my review of our third quarter financial performance. At the conclusion of these prepared remarks, we will open the line for questions. With that, I'll turn the call over to Roeland.
Thank you, Rose, and good morning to everyone joining us on the call today. Our third quarter performance reflected two distinct operating narratives. On the one hand, we had an exceptional operating quarter in our biofuel segment, where capacity utilization increased to the highest level in more than two years, exceeding 80%. Biodiesel demand remains strong as we exit the third quarter, and we expect demand to further accelerate entering 2027. Recent regulatory changes in renewable fuels markets will further narrow the RIN equivalency advantage previously enjoyed by renewable diesel producers and improve the competitive position of biodiesel producers, including ourselves. To that end, through early November, we have booked orders for more than 90% of our fourth quarter biodiesel production capacity, well ahead of prior expectations. That incredible visibility for our business provides us a good sense as to what 2027 could look like for our biofuel segment.
Even so, despite higher utilization sales volumes and price capture in the biofuel segment, the combined impact of elevated feedstock costs and derivatives losses resulted in a segment gross loss in the period. Worth noting, however, is the fact that we expect to sell 1.5 million of RINs generated from the third quarter biodiesel production and to recover $2.3 million in derivative losses tied to corresponding sales of physical inventory during the fourth quarter. In our core chemical segment, extended maintenance at dedicated process units for two separate customers reduced sales volume by 27% versus the prior year period. At Customer A, we pulled forward a planned turnaround on a dedicated production unit after the customer announced it would temporarily pause its normal order cadence to rebalance inventory levels.
Importantly, Customer A has expressed its intent to resume normal order cadence in November, and its scheduled turnaround work has since been completed. Further, it should be noted that Customer A has committed $41 million of customer-funded growth capital investment at Batesville between 2026 and 2028, as they seek to leverage the optionality afforded by our site. They are an excellent partner, one that highly values our value proposition, and they remain highly committed to proceeding with investments being made at Batesville. Even so, the turnaround at the customer production unit, together with a separate turnaround at Customer B, another long-term customer, weighed on throughput rates within the chemical segment in the period. Lower production rates with chemical segment impacted operating leverage in the third quarter, resulting in a drag on profitability. Together, these events reduced third quarter Adjusted EBITDA by approximately $4.3 million.
Importantly, in a period of short-term disruption, we controlled the controllables. Overall production units produced on plan, costs were controlled, growth initiatives moved forward as planned. Our operational rhythm was unchanged even as we adapt to short-term headwinds that we've since resolved. With both turnarounds within our chemical business completed and no major plant maintenance scheduled through the first quarter of 2027, we're positioned for a solid end to 2026 and a strong start heading into next year. Before I hand the call over to Rose Sparks for a brief overview of our third quarter results, I want to share an update on the meaningful progress we're making in advancing our strategic value creation priorities. At FutureFuel, we have three pillars of value creation: commercial growth, operational excellence, and returns-driven capital allocation.
In application, our value creation roadmap is focused on accelerating quote-to-order conversion across the chemicals opportunities pipeline, expanding production volumes with existing customers as we deepen our integration into their supply chains, capitalizing on reshoring opportunities as European chemical producers increasingly evaluate the benefits of our cost-advantaged U.S. manufacturing footprint, where natural gas costs remain substantially below those in Europe, upgrading waste streams into higher value-added products to improve average selling prices and margins, restoring our biodiesel business to optimal production rates as market conditions continue to improve, consistent with what we experienced in the third quarter. Importantly, we're not simply focused on these priorities. We're executing on them as we speak.
Beginning with the commercial focus, in the third quarter, we established a new relationship with a large European chemicals company that's reshoring production to the United States to better serve its customers and capture the cost advantages of U.S. manufacturing. Natural gas prices in Europe remain several times higher than those in the U.S., creating a significant structural cost disadvantage to European chemicals producers and making continued production increasingly uneconomic amid broader operating cost inflation. FutureFuel offers a turnkey, cost-competitive domestic manufacturing solution for chemical producers seeking to reshore production from overseas to the United States, leveraging our established infrastructure, specialized technical expertise, and scalable production capabilities. We expect to begin initial batch production with this customer in the first quarter of 2027 and to reach full production rates mid-2027. Operationally, we recently launched a productivity initiative to improve efficiency and optimize our cost structure.
Working with third-party advisors, we have identified multiple near-term opportunities to improve efficiency at Batesville, including refining waste streams into higher value-added products. Glycerin, our biodiesel waste stream, can be refined and sold for roughly three times the per-gallon value of unrefined glycerin that comes off the biodiesel stream at minimal incremental cost to us, representing a potential opportunity to us of $5 million-$10 million beginning in 2027. In an inflationary environment, we also continue to pass through higher energy, material, and labor costs under the customer agreements that provide us cost indexing. You'll hear more about the cost actions being taken in our business over the coming quarters. We're early days, but the opportunities are significant. Our capital allocation priorities remain unchanged, with an emphasis on disciplined, return-driven investments, decisions designed to maximize long-term shareholder value.
We will continue to prioritize customer-funded investments at Batesville and the working capital needed to support feedstock purchases while maintaining flexibility for our return of capital priorities. A note on liquidity. We're very focused on building our cash position back to $50 million over the next year. Working capital for feedstock purchases remain elevated, which has created a significant draw on available liquidity. It isn't a surprise to us, and we're ready for it, but it also means that we intend to measure our approach towards share repurchases and/or increasing the cash dividend until we further bolster the balance sheet, which we'll fully intend to do. One final comment around customer-driven capital investments. This year, customer-funded growth capital was $16.1 million, or approximately 50% of our total CapEx. Between 2028 and 2029, we currently expect customers to invest another $15 million-$20 million in our Batesville site.
As we mentioned in the past, these third-party investments not only make us more valuable to our customers, they entrench the relationship, creating an uncommonly highly synergistic partnership. As the only domestic specialty chemicals platform that combines decades of technical expertise, complex chemical synthesis capabilities, and integrated cost-competitive U.S. production platform, the value of our business is very clear. Our customers rely on us not simply as a supplier, but as an extension of their manufacturing operations, allowing them to reduce capital intensity, maintain stringent quality standards, and reliable scale production. From there, we will focus on building a leaner, more profitable business that delivers greater operating leverage over time. New customer acquisition and growing share of wallet with existing partners will drive the opportunity, but cost rationalization will be critically important as well.
It's an exciting time for the business, and we appreciate the partnership of our partners, customers, and shareholders as we move into a new phase of value creation. With that, I hand the call over to Rose for her prepared remarks.
Thank you, Roeland, and good morning to all those joining us. Today, I will provide a high-level overview of our third quarter financial performance, including a discussion of our balance sheet and liquidity profile at quarter end. Total revenue increased 361.3% to $104.7 million during the third quarter, up from $22.7 million last year. The $82 million increase comprised $36.3 million from volume and product mix, and $45.7 million from pricing, principally in the biofuel segment. Total gross loss was $5.4 million during the third quarter of 2026, versus a gross loss of $6.5 million during the third quarter of 2025. Third quarter results include $8.7 million of net derivative losses, comprising $8.3 million of realized losses and $0.4 million of unrealized losses. Included in realized derivative losses is $2.3 million associated with physical inventory not yet sold, which is expected to be recovered in the fourth quarter.
At September 30th, the company held approximately 0.7 million internally generated RINs with a value of $1.5 million for delivery in the fourth quarter. The related sales benefit was not included in third quarter results and will be recognized when those RINs are transferred. The company reported a net loss of $8.4 million during the third quarter of 2026, versus a net loss of $9.2 million in the third quarter of 2025. Adjusted EBITDA was a loss of $4.9 million during the third quarter of 2026, versus $5.3 million loss during the third quarter of 2025. Turning to the chemical segment revenue was $16.9 million in the third quarter of 2026, up 8.6% from $15.6 million in the third quarter of 2025. The increase reflected contribution from higher volume and product mix.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
5 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
